PubMed Health⌕ Search

PubMed · 3779735

Right ventricular failure associated with left ventricular failure.

Abstract

RV and LV failure frequently coexist. Experimental evidence suggests that RV failure results from a primary insult to the right ventricle and an increase in pulmonary vascular resistance. LV failure results in an elevation of the left atrial pressure and thereby a reduction in the transpulmonary hydrostatic gradient. Because RV function depends on the contraction of the left ventricle, this contribution is reduced during LV failure. Treatment should be aimed first at restoring LV function. If RV failure persists and is not due to a simple mechanical problem, treatment of RV failure should be commenced. If volume loading, inotropes, and pH adjustments do not result in adequate RV output, a mechanical assist device should be considered. RHBP is the most powerful device, and it is capable of restoring systemic perfusion even when there is no residual RV function. Clinical results with this device have been most encouraging--most patients demonstrate improved RV function and a decrease in pulmonary vascular resistance after several days of treatment, allowing them to be weaned from assist. However, this technique is very invasive and requires constant close attention. PABC is a simple but less powerful assist device. Experimental studies suggest that if RV function is not extremely depressed--cardiac output is greater than 50 percent of normal--PABC may be effective in restoring systemic perfusion to normal levels. Current results suggest that RHBP remains the gold standard for severe RV failure, but further clinical experience with PABC may more clearly define its role in the management of RV failure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P A Spence, C E Baylis, C M Peniston, T A Salerno. 1987. Right ventricular failure associated with left ventricular failure.. https://pubmed.ncbi.nlm.nih.gov/3779735/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Elevated 5-oxoproline levels and adverse outcomes in heart failure: Association with renal cortical OPLAH loss in a multi-comorbidity model.

BACKGROUND: Heart failure (HF) progression is closely linked to oxidative stress. 5-Oxoproline (5-OP), a product of glutathione degradation, is normally metabolized by 5-oxoprolinase (OPLAH) but accumulates when the gamma-glutamyl cycle is disrupted. Here, we investigated the clinical characteristics of circulating 5-OP, its proteomic correlates, and the associations to outcome in HF. METHODS: In serum of 823 BIOSTAT-CHF patients, 5-OP was quantified by validated liquid chromatography-mass spectrometry and analyzed for associations with clinical outcomes. Proteomic correlates were identified across 355 OLINK proteins using stability selection with Minimax Concave Penalty regression. Mechanistic context was evaluated in a multi-comorbidity, large-animal cardio-kidney-metabolic (CKM) model with regional OPLAH assessment. RESULTS: Higher 5-OP was associated with worse renal function (eGFR declining across 5-OP tertiles, 67.9 to 60.2 mL/min/1.73 m2; p = 0.0012) and higher all-cause mortality (HR 1.55, 95% CI 1.11-2.17, p = 0.010). Per SD increase in log-5-OP, risk for the 2-year composite endpoint increased (HR 1.27, 95% CI 1.05-1.53), with broadly similar associations across CKD strata (interaction p = 0.63). TGF-α was the most robust proteomic correlate (π = 0.70; empirical permutation p = 0.001). In CKM swine, circulating 5-OP was elevated and renal cortical OPLAH protein, but not cardiac OPLAH, was selectively reduced, consistent with a renal contribution to systemic 5-OP elevation. CONCLUSION: Circulating 5-OP identifies HF patients at higher risk and is robustly associated with TGF-α. In a translational swine model, selective loss of renal cortical OPLAH provides tissue context supporting a renal contribution to systemic 5-OP elevation in cardiorenal syndrome.

Heart Failure↗

Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory.

Evolving statistical concepts and innovative trial designs for heart failure (HF) clinical trials seek to improve the conduct, efficiency, and likelihood of meaningful evidence generation crucial for advancing therapeutic development and optimizing patient care. HF trials with conventional statistical frameworks often require large sample sizes, long follow-up times, and high cost to generate sufficient evidence. Novel statistical methodologies would be of interest if they could address these issues while retaining or enhancing the clinical relevance and reliability of results. The HFC (Heart Failure Collaboratory), comprising clinical investigators, clinicians, statisticians, patients, government representatives, payors, and industry collaborators, leads efforts to improve HF research methodologies. HFC discussions have included statistical concepts such as the estimand framework, HR drift, and analytic methods, including the win ratio and restricted mean survival time, that have not been used frequently in HF trials. The estimand framework encourages precise definition and alignment of trial objectives with trial design. The win ratio method attempts to incorporate and prioritize multiple clinically meaningful outcomes by using a hierarchy of clinical importance. The restricted mean survival time provides an alternative to the HR as a measure of therapeutic effect by quantifying the mean time gained or lost during a fixed time after randomization. This paper provides a critical review of some evolving HF trial design methodologies and statistical concepts for the HF community as discussed within the HFC. Our goal is to foster collaboration among diverse stakeholders and advance the development of effective treatments and improve patient care outcomes.

Heart Failure↗

[Circulatory mechanical support. State of the art].

Despite advances in medical treatment, the prognosis of advanced heart failure remains poor. The number of hospitalizations for heart failure exacerbations continues to increase and most patients will ultimately die of complications related to heart failure. Implantable left ventricular assist devices (LVAD) are currently in use throughout the world with increasing frequency. This paper is a comprehensive review about mechanical support, focusing on a general description of the different LVAD, complications and mortality.

Heart Failure↗